These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16538116)

  • 1. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test.
    Heresbach D; Manfredi S; D'halluin PN; Bretagne JF; Branger B
    Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):427-33. PubMed ID: 16538116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update.
    Hewitson P; Glasziou P; Watson E; Towler B; Irwig L
    Am J Gastroenterol; 2008 Jun; 103(6):1541-9. PubMed ID: 18479499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds.
    Jørgensen OD; Kronborg O; Fenger C
    Gut; 2002 Jan; 50(1):29-32. PubMed ID: 11772963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data.
    Moayyedi P; Achkar E
    Am J Gastroenterol; 2006 Feb; 101(2):380-4. PubMed ID: 16454847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for colorectal cancer using the faecal occult blood test, Hemoccult.
    Hewitson P; Glasziou P; Irwig L; Towler B; Watson E
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD001216. PubMed ID: 17253456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study.
    Faivre J; Dancourt V; Lejeune C; Tazi MA; Lamour J; Gerard D; Dassonville F; Bonithon-Kopp C
    Gastroenterology; 2004 Jun; 126(7):1674-80. PubMed ID: 15188160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of the effectiveness of population screening for colorectal cancer.
    Kerr J; Day P; Broadstock M; Weir R; Bidwell S
    N Z Med J; 2007 Jul; 120(1258):U2629. PubMed ID: 17653247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
    Mandel JS; Church TR; Ederer F; Bond JH
    J Natl Cancer Inst; 1999 Mar; 91(5):434-7. PubMed ID: 10070942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is FOB screening really the answer for lowering mortality in colorectal cancer?
    Autier P; Boyle P; Buyse M; Bleiberg H
    Recent Results Cancer Res; 2003; 163():254-63; discussion 264-6. PubMed ID: 12903860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Screening Compliance on Long-term Reductions in All-Cause and Colorectal Cancer Mortality.
    Shaukat A; Kaalby L; Baatrup G; Kronborg O; Duval S; Shyne M; Mandel JS; Church TR
    Clin Gastroenterol Hepatol; 2021 May; 19(5):967-975.e2. PubMed ID: 32634624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.
    Kronborg O; Jørgensen OD; Fenger C; Rasmussen M
    Scand J Gastroenterol; 2004 Sep; 39(9):846-51. PubMed ID: 15513382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of faecal occult blood test screening for colorectal cancer: worse prognosis for screening refusers.
    Niv Y; Lev-El M; Fraser G; Abuksis G; Tamir A
    Gut; 2002 Jan; 50(1):33-7. PubMed ID: 11772964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up.
    Scholefield JH; Moss SM; Mangham CM; Whynes DK; Hardcastle JD
    Gut; 2012 Jul; 61(7):1036-40. PubMed ID: 22052062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing colorectal cancer or early diagnosis: Which is best? A re-analysis of the U.S. Preventive Services Task Force Evidence Report.
    Swartz AW; Eberth JM; Strayer SM
    Prev Med; 2019 Jan; 118():104-112. PubMed ID: 30367971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for colorectal cancer using the faecal occult blood test, hemoccult.
    Towler BP; Irwig L; Glasziou P; Weller D; Kewenter J
    Cochrane Database Syst Rev; 2000; (2):CD001216. PubMed ID: 10796760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term risk of colorectal cancer after negative colonoscopy in a Danish gFOBT screening cohort.
    Bjerrum A; Andersen O; Fischer A; Lindebjerg J; Lynge E
    Int J Cancer; 2017 Aug; 141(3):503-511. PubMed ID: 28463410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study.
    Libby G; Brewster DH; McClements PL; Carey FA; Black RJ; Birrell J; Fraser CG; Steele RJ
    Br J Cancer; 2012 Jul; 107(2):255-9. PubMed ID: 22735907
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.